BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van den Bergh MR, Spijkerman J, Swinnen KM, François NA, Pascal TG, Borys D, Schuerman L, Ijzerman EP, Bruin JP, van der Ende A, Veenhoven RH, Sanders EA. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis 2013;56:e30-9. [PMID: 23118268 DOI: 10.1093/cid/cis922] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Løchen A, Anderson R. Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations. Clinical Microbiology and Infection 2020;26:60-70. [DOI: 10.1016/j.cmi.2019.04.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Hausdorff WP, Hoet B, Adegbola RA. Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough. Expert Rev Vaccines 2015;14:413-28. [PMID: 25266168 DOI: 10.1586/14760584.2015.965160] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
3 Jalalvand F, Littorin N, Su YC, Riesbeck K. Impact of immunization with Protein F on pulmonary clearance of nontypeable Haemophilus influenzae. Vaccine 2014;32:2261-4. [PMID: 24631068 DOI: 10.1016/j.vaccine.2014.02.082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
4 Pichichero ME. Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother 2013;9:2505-23. [PMID: 23955057 DOI: 10.4161/hv.26109] [Cited by in Crossref: 111] [Cited by in F6Publishing: 94] [Article Influence: 12.3] [Reference Citation Analysis]
5 Smith-Vaughan HC, Chang AB, Sarovich DS, Marsh RL, Grimwood K, Leach AJ, Morris PS, Price EP. Absence of an important vaccine and diagnostic target in carriage- and disease-related nontypeable Haemophilus influenzae. Clin Vaccine Immunol 2014;21:250-2. [PMID: 24285816 DOI: 10.1128/CVI.00632-13] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
6 Hammitt LL, Akech DO, Morpeth SC, Karani A, Kihuha N, Nyongesa S, Bwanaali T, Mumbo E, Kamau T, Sharif SK, Scott JA. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health 2014;2:e397-405. [PMID: 25103393 DOI: 10.1016/S2214-109X(14)70224-4] [Cited by in Crossref: 147] [Cited by in F6Publishing: 80] [Article Influence: 18.4] [Reference Citation Analysis]
7 Tin Tin Htar M, Sings HL, Syrochkina M, Taysi B, Hilton B, Schmitt H, Gessner BD, Jodar L. The impact of pneumococcal conjugate vaccines on serotype 19A nasopharyngeal carriage. Expert Review of Vaccines 2019;18:1243-70. [DOI: 10.1080/14760584.2019.1675521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Moreno-Pérez D, Álvarez García FJ, Arístegui Fernández J, Cilleruelo Ortega MJ, Corretger Rauet JM, García Sánchez N, Hernández Merino A, Hernández-Sampelayo Matos T, Merino Moína M, Ortigosa del Castillo L, Ruiz-Contreras J; en representación del Comité Asesor de Vacunas de la Asociación Española de Pediatría (CAV-AEP). [Immunisation schedule of the Spanish Association of Paediatrics: 2016 recommendations]. An Pediatr (Barc) 2016;84:60.e1-13. [PMID: 26589473 DOI: 10.1016/j.anpedi.2015.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Vesikari T, Forsten A, Seppä I, Kaijalainen T, Puumalainen T, Soininen A, Traskine M, Lommel P, Schoonbroodt S, Hezareh M, Moreira M, Borys D, Schuerman L. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland. J Pediatric Infect Dis Soc 2016;5:237-48. [PMID: 27125273 DOI: 10.1093/jpids/piw010] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 9.7] [Reference Citation Analysis]
10 Isturiz R, Sings HL, Hilton B, Arguedas A, Reinert R, Jodar L. Streptococcus pneumoniae serotype 19A: worldwide epidemiology. Expert Review of Vaccines 2017;16:1007-27. [DOI: 10.1080/14760584.2017.1362339] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 12.6] [Reference Citation Analysis]
11 van Werkhoven CH, Huijts SM. Vaccines to Prevent Pneumococcal Community-Acquired Pneumonia. Clin Chest Med 2018;39:733-52. [PMID: 30390745 DOI: 10.1016/j.ccm.2018.07.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
12 Leach AJ, Wigger C, Beissbarth J, Woltring D, Andrews R, Chatfield MD, Smith-Vaughan H, Morris PS. General health, otitis media, nasopharyngeal carriage and middle ear microbiology in Northern Territory Aboriginal children vaccinated during consecutive periods of 10-valent or 13-valent pneumococcal conjugate vaccines. Int J Pediatr Otorhinolaryngol 2016;86:224-32. [PMID: 27260611 DOI: 10.1016/j.ijporl.2016.05.011] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 8.5] [Reference Citation Analysis]
13 Sigurdsson S, Kristinsson KG, Erlendsdóttir H, Hrafnkelsson B, Haraldsson Á. Decreased Incidence of Respiratory Infections in Children After Vaccination with Ten-valent Pneumococcal Vaccine. Pediatric Infectious Disease Journal 2015;34:1385-90. [DOI: 10.1097/inf.0000000000000899] [Cited by in Crossref: 31] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]
14 Pickering J, Binks MJ, Beissbarth J, Hare KM, Kirkham LA, Smith-Vaughan H. A PCR-high-resolution melt assay for rapid differentiation of nontypeable Haemophilus influenzae and Haemophilus haemolyticus. J Clin Microbiol 2014;52:663-7. [PMID: 24478508 DOI: 10.1128/JCM.02191-13] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
15 Siggins MK, Gill SK, Langford PR, Li Y, Ladhani SN, Tregoning JS. PHiD-CV induces anti-Protein D antibodies but does not augment pulmonary clearance of nontypeable Haemophilus influenzae in mice. Vaccine 2015;33:4954-61. [PMID: 26212006 DOI: 10.1016/j.vaccine.2015.07.034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
16 Otczyk DC, Cripps AW. Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines. Pneumonia (Nathan) 2013;2:2-15. [PMID: 31463182 DOI: 10.15172/pneu.2013.2/229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Sriram KB, Cox AJ, Clancy RL, Slack MPE, Cripps AW. Nontypeable Haemophilus influenzae and chronic obstructive pulmonary disease: a review for clinicians. Crit Rev Microbiol 2018;44:125-42. [PMID: 28539074 DOI: 10.1080/1040841X.2017.1329274] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
18 Berglund J, Vink P, Tavares Da Silva F, Lestrate P, Boutriau D. Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults. Clin Vaccine Immunol 2014;21:56-65. [PMID: 24173029 DOI: 10.1128/CVI.00430-13] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
19 Wu DB, Roberts C, Lee VW, Hong LW, Tan KK, Mak V, Lee KK. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong. Hum Vaccin Immunother 2016;12:403-16. [PMID: 26451658 DOI: 10.1080/21645515.2015.1067351] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
20 Otsuka T, Brauer AL, Kirkham C, Sully EK, Pettigrew MM, Kong Y, Geller BL, Murphy TF. Antimicrobial activity of antisense peptide-peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms. J Antimicrob Chemother 2017;72:137-44. [PMID: 27986898 DOI: 10.1093/jac/dkw384] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
21 Santos-Cortez RLP, Bhutta MF, Earl JP, Hafrén L, Jennings M, Mell JC, Pichichero ME, Ryan AF, Tateossian H, Ehrlich GD. Panel 3: Genomics, precision medicine and targeted therapies. Int J Pediatr Otorhinolaryngol 2020;130 Suppl 1:109835. [PMID: 32007292 DOI: 10.1016/j.ijporl.2019.109835] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Hausdorff WP, Hanage WP. Interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother 2016;12:358-74. [PMID: 26905681 DOI: 10.1080/21645515.2015.1118593] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 9.8] [Reference Citation Analysis]
23 Bröker M, Berti F, Schneider J, Vojtek I. Polysaccharide conjugate vaccine protein carriers as a "neglected valency" - Potential and limitations. Vaccine 2017;35:3286-94. [PMID: 28487056 DOI: 10.1016/j.vaccine.2017.04.078] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
24 Wang BC, Chaiyakunapruk N, Zhu S, Babigumira JB, Furnback W, Chitale R, Gamil A, Zhao K, Wasserman M. A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006-2019). Expert Rev Vaccines 2021;:1-14. [PMID: 33682584 DOI: 10.1080/14760584.2021.1894933] [Reference Citation Analysis]
25 Malvisi L, Taddei L, Yarraguntla A, Wilkinson TMA, Arora AK; AERIS Study Group. Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepoints. Respir Res 2021;22:67. [PMID: 33627095 DOI: 10.1186/s12931-021-01653-8] [Reference Citation Analysis]
26 Pickering JL, Prosser A, Corscadden KJ, de Gier C, Richmond PC, Zhang G, Thornton RB, Kirkham LA. Haemophilus haemolyticus Interaction with Host Cells Is Different to Nontypeable Haemophilus influenzae and Prevents NTHi Association with Epithelial Cells. Front Cell Infect Microbiol 2016;6:50. [PMID: 27242968 DOI: 10.3389/fcimb.2016.00050] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
27 Pichichero ME. Ten-Year Study of Acute Otitis Media in Rochester, NY. Pediatr Infect Dis J 2016;35:1027-32. [PMID: 27182898 DOI: 10.1097/INF.0000000000001216] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 5.6] [Reference Citation Analysis]
28 Slack MPE. The evidence for non-typeable Haemophilus influenzae as a causative agent of childhood pneumonia. Pneumonia (Nathan) 2017;9:9. [PMID: 28702311 DOI: 10.1186/s41479-017-0033-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
29 Sveinsdóttir H, Björnsdóttir JB, Erlendsdóttir H, Hjálmarsdóttir MÁ, Hrafnkelsson B, Haraldsson Á, Kristinsson KG, Haraldsson G. The Effect of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine on H. influenzae in Healthy Carriers and Middle Ear Infections in Iceland. J Clin Microbiol 2019;57:e00116-19. [PMID: 31068412 DOI: 10.1128/JCM.00116-19] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Lister AJJ, Le CF, Cheah ESG, Desa MNM, Cleary DW, Clarke SC. Serotype distribution of invasive, non-invasive and carried Streptococcus pneumoniae in Malaysia: a meta-analysis. Pneumonia (Nathan) 2021;13:9. [PMID: 34030731 DOI: 10.1186/s41479-021-00086-7] [Reference Citation Analysis]
31 Principi N, Esposito S. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease. Expert Rev Vaccines 2015;14:1359-66. [PMID: 26289973 DOI: 10.1586/14760584.2015.1075884] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
32 Nunes MC, Moreira M, Koen A, van Niekerk N, Jose L, Cutland CL, François N, Schoonbroodt S, Ruiz-Guiñazú J, Yarzabal JP, Borys D, Schuerman L, Madhi SA. Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials. Expert Rev Vaccines 2020;19:1177-89. [PMID: 33245004 DOI: 10.1080/14760584.2020.1853533] [Reference Citation Analysis]
33 Trück J, Mitchell R, Jawad S, Clutterbuck EA, Snape MD, Kelly DF, Voysey M, Pollard AJ. Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule. Pediatr Infect Dis J 2017;36:e130-5. [PMID: 28027283 DOI: 10.1097/INF.0000000000001497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
34 Dagan R. Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation. Expert Rev Vaccines 2019;18:641-61. [PMID: 31230486 DOI: 10.1080/14760584.2019.1627207] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
35 Slack MPE, Cripps AW, Grimwood K, Mackenzie GA, Ulanova M. Invasive Haemophilus influenzae Infections after 3 Decades of Hib Protein Conjugate Vaccine Use. Clin Microbiol Rev 2021;34:e0002821. [PMID: 34076491 DOI: 10.1128/CMR.00028-21] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Knol MJ, van der Ende A. Continuous surveillance of invasive pneumococcal disease is key. Lancet Infect Dis 2021;21:13-4. [PMID: 32702304 DOI: 10.1016/S1473-3099(20)30294-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Best EJ, Walls T, Souter M, Neeff M, Anderson T, Salkeld L, Ahmad Z, Mahadevan M, Walker C, Murdoch D, Mills N. Pneumococcal vaccine impact on otitis media microbiology: A New Zealand cohort study before and after the introduction of PHiD-CV10 vaccine. Vaccine 2016;34:3840-7. [DOI: 10.1016/j.vaccine.2016.05.041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
38 Fortanier AC, Venekamp RP, Boonacker CW, Hak E, Schilder AG, Sanders EA, Damoiseaux RA. Pneumococcal conjugate vaccines for preventing acute otitis media in children. Cochrane Database Syst Rev 2019;5:CD001480. [PMID: 31135969 DOI: 10.1002/14651858.CD001480.pub5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
39 van Werkhoven CH, Bonten MJ. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly? Future Microbiology 2015;10:1405-13. [DOI: 10.2217/fmb.15.80] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
40 Thors V, Morales-Aza B, Pidwill G, Vipond I, Muir P, Finn A. Population density profiles of nasopharyngeal carriage of 5 bacterial species in pre-school children measured using quantitative PCR offer potential insights into the dynamics of transmission. Hum Vaccin Immunother 2016;12:375-82. [PMID: 26367344 DOI: 10.1080/21645515.2015.1090069] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
41 van Werkhoven CH, Hollingsworth RC, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Sanders EA, Bonten MJ. Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly. Vaccine 2016;34:3275-82. [PMID: 27171754 DOI: 10.1016/j.vaccine.2016.05.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
42 Knol MJ, Wagenvoort GH, Sanders EA, Elberse K, Vlaminckx BJ, de Melker HE, van der Ende A. Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands. Emerg Infect Dis 2015;21:2040-4. [PMID: 26488415 DOI: 10.3201/eid2111.140780] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
43 Wasserman M, Sings HL, Jones D, Pugh S, Moffatt M, Farkouh R. Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Review of Vaccines 2018;17:71-8. [DOI: 10.1080/14760584.2018.1409116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
44 Sáez-Llorens X, Rowley S, Wong D, Rodríguez M, Calvo A, Troitiño M, Salas A, Vega V, Castrejón MM, Lommel P, Pascal TG, Hausdorff WP, Borys D, Ruiz-Guiñazú J, Ortega-Barría E, Yarzabal JP, Schuerman L. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial. Hum Vaccin Immunother 2017;13:1-16. [PMID: 28368738 DOI: 10.1080/21645515.2017.1287640] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
45 Moreno-pérez D, Álvarez García F, Arístegui Fernández J, Cilleruelo Ortega M, Corretger Rauet J, García Sánchez N, Hernández Merino A, Hernández-sampelayo Matos T, Merino Moína M, del Castillo LO, Ruiz-contreras J. Immunisation schedule of the Spanish Association of Paediatrics: 2016 recommendations. Anales de Pediatría (English Edition) 2016;84:60.e1-60.e13. [DOI: 10.1016/j.anpede.2015.11.007] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Plosker GL. 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D-Conjugate Vaccine: A Review in Infants and Children. Pediatr Drugs 2014;16:425-44. [DOI: 10.1007/s40272-014-0089-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
47 Hare KM, Smith-vaughan HC, Leach AJ, Pizzutto SJ, Mccallum GB, Chang AB. Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine. Vaccine 2018;36:1736-42. [DOI: 10.1016/j.vaccine.2018.02.054] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
48 Perdrizet J, Farkouh RA, Horn EK, Hayford K, Sings HL, Wasserman MD. The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines. Expert Rev Vaccines 2022;:1-13. [PMID: 35191368 DOI: 10.1080/14760584.2022.2040989] [Reference Citation Analysis]
49 Heinz E. The return of Pfeiffer's bacillus: Rising incidence of ampicillin resistance in Haemophilus influenzae. Microb Genom 2018;4. [PMID: 30207515 DOI: 10.1099/mgen.0.000214] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
50 Madhi SA, Moreira M, Koen A, van Niekerk N, de Gouveia L, Jose L, Cutland CL, François N, Schoonbroodt S, Ruiz-Guiñazú J, Yarzabal JP, Borys D, Schuerman L. Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa. Vaccine 2020;38:2350-60. [PMID: 32035706 DOI: 10.1016/j.vaccine.2020.01.062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Osman KL, Jefferies JM, Woelk CH, Cleary DW, Clarke SC. The adhesins of non-typeable Haemophilus influenzae. Expert Rev Anti Infect Ther 2018;16:187-96. [PMID: 29415569 DOI: 10.1080/14787210.2018.1438263] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
52 Thors V, Christensen H, Morales-Aza B, Oliver E, Sikora P, Vipond I, Muir P, Finn A. High-density Bacterial Nasal Carriage in Children Is Transient and Associated With Respiratory Viral Infections-Implications for Transmission Dynamics. Pediatr Infect Dis J 2019;38:533-8. [PMID: 30985547 DOI: 10.1097/INF.0000000000002256] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
53 Bosch AATM, van Houten MA, Bruin JP, Wijmenga-Monsuur AJ, Trzciński K, Bogaert D, Rots NY, Sanders EAM. Nasopharyngeal carriage of Streptococcus pneumoniae and other bacteria in the 7th year after implementation of the pneumococcal conjugate vaccine in the Netherlands. Vaccine 2016;34:531-9. [PMID: 26667610 DOI: 10.1016/j.vaccine.2015.11.060] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 8.0] [Reference Citation Analysis]
54 Lee H, Choi EH, Lee HJ. Efficacy and effectiveness of extended-valency pneumococcal conjugate vaccines. Korean J Pediatr 2014;57:55-66. [PMID: 24678328 DOI: 10.3345/kjp.2014.57.2.55] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
55 Pumarola F, Marès J, Losada I, Minguella I, Moraga F, Tarragó D, Aguilera U, Casanovas JM, Gadea G, Trías E, Cenoz S, Sistiaga A, García-Corbeira P, Pirçon JY, Marano C, Hausdorff WP. Microbiology of bacteria causing recurrent acute otitis media (AOM) and AOM treatment failure in young children in Spain: shifting pathogens in the post-pneumococcal conjugate vaccination era. Int J Pediatr Otorhinolaryngol 2013;77:1231-6. [PMID: 23746414 DOI: 10.1016/j.ijporl.2013.04.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 5.2] [Reference Citation Analysis]
56 Bergenfelz C, Hakansson AP. Streptococcus pneumoniae Otitis Media Pathogenesis and How It Informs Our Understanding of Vaccine Strategies. Curr Otorhinolaryngol Rep 2017;5:115-24. [PMID: 28616365 DOI: 10.1007/s40136-017-0152-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
57 Clarke C, Bakaletz LO, Ruiz-Guiñazú J, Borys D, Mrkvan T. Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage. Expert Rev Vaccines 2017;16:1-14. [PMID: 28571504 DOI: 10.1080/14760584.2017.1333905] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
58 Wang XJ, Saha A, Zhang XH. Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia. Cost Eff Resour Alloc 2017;15:17. [PMID: 28852326 DOI: 10.1186/s12962-017-0079-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
59 Leach AJ, Wigger C, Hare K, Hampton V, Beissbarth J, Andrews R, Chatfield M, Smith-Vaughan H, Morris PS. Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine. BMC Pediatr 2015;15:162. [PMID: 26482232 DOI: 10.1186/s12887-015-0483-8] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 6.6] [Reference Citation Analysis]
60 Sigurdsson S, Erlendsdóttir H, Quirk SJ, Kristjánsson J, Hauksson K, Andrésdóttir BDI, Jónsson AJ, Halldórsson KH, Sæmundsson Á, Ólason ÓH, Hrafnkelsson B, Kristinsson KG, Haraldsson Á. Pneumococcal vaccination: Direct and herd effect on carriage of vaccine types and antibiotic resistance in Icelandic children. Vaccine 2017;35:5242-8. [PMID: 28823621 DOI: 10.1016/j.vaccine.2017.08.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
61 Fortanier AC, Venekamp RP, Boonacker CW, Hak E, Schilder AG, Sanders EA, Damoiseaux RA. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane Database Syst Rev 2014;:CD001480. [PMID: 24696098 DOI: 10.1002/14651858.CD001480.pub4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
62 Krone CL, Oja AE, van de Groep K, Sanders EA, Bogaert D, Trzciński K. Dried Saliva Spots: A Robust Method for Detecting Streptococcus pneumoniae Carriage by PCR. Int J Mol Sci 2016;17:343. [PMID: 26959014 DOI: 10.3390/ijms17030343] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
63 Plosker GL. 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Infants, Children, and Adolescents. Pediatr Drugs 2013;15:403-23. [DOI: 10.1007/s40272-013-0047-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
64 Vissers M, Wijmenga-Monsuur AJ, Knol MJ, Badoux P, van Houten MA, van der Ende A, Sanders EAM, Rots NY. Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands. PLoS One 2018;13:e0194823. [PMID: 29601605 DOI: 10.1371/journal.pone.0194823] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
65 O'Grady KA, Grimwood K, Cripps A, Mulholland EK, Morris P, Torzillo PJ, Wood N, Smith-Vaughan H, Revell A, Wilson A, Van Asperen P, Richmond P, Thornton R, Rablin S, Chang AB. Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial. Trials 2013;14:282. [PMID: 24010917 DOI: 10.1186/1745-6215-14-282] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
66 de Gier C, Granland CM, Pickering JL, Walls T, Bhuiyan M, Mills N, Richmond PC, Best EJ, Thornton RB, Kirkham LS. PCV7- and PCV10-Vaccinated Otitis-Prone Children in New Zealand Have Similar Pneumococcal and Haemophilus influenzae Densities in Their Nasopharynx and Middle Ear. Vaccines (Basel) 2019;7:E14. [PMID: 30708945 DOI: 10.3390/vaccines7010014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
67 O’grady KF, Chang AB, Grimwood K. Vaccines for children and adults with chronic lung disease: efficacy against acute exacerbations. Expert Review of Respiratory Medicine 2013;8:43-55. [DOI: 10.1586/17476348.2014.852960] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
68 Klok RM, Lindkvist R, Ekelund M, Farkouh RA, Strutton DR. Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden. Clinical Therapeutics 2013;35:119-34. [DOI: 10.1016/j.clinthera.2012.12.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
69 Moreno-pérez D, Álvarez García F, Arístegui Fernández J, Cilleruelo Ortega M, Corretger Rauet J, García Sánchez N, Hernández Merino A, Hernández-sampelayo Matos T, Merino Moína M, Ortigosa del Castillo L, Ruiz-contreras J. Calendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2014. Anales de Pediatría 2014;80:55.e1-55.e37. [DOI: 10.1016/j.anpedi.2013.10.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
70 Palmu AA, Toropainen M, Kaijalainen T, Siira L, Lahdenkari M, Nieminen H, Syrjänen RK, Kilpi TM, Jokinen J. Direct and Indirect Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine Against Carriage in a Cluster Randomized Trial. Pediatr Infect Dis J 2017;36:1193-200. [PMID: 28737627 DOI: 10.1097/INF.0000000000001705] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
71 Pettigrew MM, Alderson MR, Bakaletz LO, Barenkamp SJ, Hakansson AP, Mason KM, Nokso-Koivisto J, Patel J, Pelton SI, Murphy TF. Panel 6: Vaccines. Otolaryngol Head Neck Surg 2017;156:S76-87. [PMID: 28372533 DOI: 10.1177/0194599816632178] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
72 Avila-Aguero ML, Ulloa-Gutierrez R, Falleiros-Arlant LH, Porras O. Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A? Expert Rev Vaccines 2017;16:1-4. [PMID: 28535704 DOI: 10.1080/14760584.2017.1334555] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
73 Leach AJ, Wigger C, Andrews R, Chatfield M, Smith-Vaughan H, Morris PS. Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules. BMC Pediatr 2014;14:200. [PMID: 25109288 DOI: 10.1186/1471-2431-14-200] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
74 Beissbarth J, Wilson N, Arrowsmith B, Binks MJ, Oguoma VM, Lawrence K, Llewellyn A, Mulholland EK, Santosham M, Morris PS, Smith-Vaughan HC, Cheng AC, Leach AJ. Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial. Vaccine 2021;39:2264-73. [PMID: 33766422 DOI: 10.1016/j.vaccine.2021.03.032] [Reference Citation Analysis]
75 van den Bergh MR, Spijkerman J, François N, Swinnen K, Borys D, Schuerman L, Veenhoven RH, Sanders EA. Immunogenicity, Safety and Reactogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable H. influenzae Protein D Conjugate Vaccine Coadministered With DTPa-IPV-Hib in Dutch Children: A Randomized Controlled Trial. Pediatr Infect Dis J 2016;35:e206-19. [PMID: 27097348 DOI: 10.1097/INF.0000000000001170] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
76 Khan MN, Ren D, Kaur R, Basha S, Zagursky R, Pichichero ME. Developing a vaccine to prevent otitis media caused by nontypeable Haemophilus influenzae. Expert Rev Vaccines 2016;15:863-78. [PMID: 26894630 DOI: 10.1586/14760584.2016.1156539] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
77 Hua CZ, Hu WL, Shang SQ, Li JP, Hong LQ, Yan J. Serum Concentrations of Antibodies against Outer Membrane Protein P6, Protein D, and T- and B-Cell Combined Antigenic Epitopes of Nontypeable Haemophilus influenzae in Children and Adults of Different Ages. Clin Vaccine Immunol 2016;23:155-61. [PMID: 26677200 DOI: 10.1128/CVI.00506-15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
78 Van Eldere J, Slack MP, Ladhani S, Cripps AW. Non-typeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect Dis 2014;14:1281-92. [PMID: 25012226 DOI: 10.1016/S1473-3099(14)70734-0] [Cited by in Crossref: 191] [Cited by in F6Publishing: 99] [Article Influence: 23.9] [Reference Citation Analysis]
79 Brandileone MC, Zanella RC, Almeida SCG, Brandao AP, Ribeiro AF, Carvalhanas TMP, Sato H, Andrade AL, Verani JR; Pneumococcal Carriage Study Group. Effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae among children in São Paulo, Brazil. Vaccine 2016;34:5604-11. [PMID: 27692770 DOI: 10.1016/j.vaccine.2016.09.027] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 9.5] [Reference Citation Analysis]
80 Murphy TF. Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now. Clin Vaccine Immunol 2015;22:459-66. [PMID: 25787137 DOI: 10.1128/CVI.00089-15] [Cited by in Crossref: 69] [Cited by in F6Publishing: 41] [Article Influence: 9.9] [Reference Citation Analysis]
81 Hammitt LL, Crane RJ, Karani A, Mutuku A, Morpeth SC, Burbidge P, Goldblatt D, Kamau T, Sharif S, Mturi N, Scott JA. Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study. Lancet Glob Health 2016;4:e185-94. [PMID: 26853149 DOI: 10.1016/S2214-109X(15)00316-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
82 Wouters I, Desmet S, Van Heirstraeten L, Herzog SA, Beutels P, Verhaegen J, Goossens H, Van Damme P, Malhotra-Kumar S, Theeten H; NPcarriage Study Group. How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018. Euro Surveill 2020;25. [PMID: 32046817 DOI: 10.2807/1560-7917.ES.2020.25.5.1900303] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
83 Rahman T, de Gier C, Orami T, Seppanen EJ, Granland CM, Francis JP, Michael A, Yoannes M, Corscadden KJ, Ford RL, Martinovich KM, Jacoby P, van den Biggelaar AHJ, Lehmann D, Richmond PC, Pomat WS, Thornton RB, Kirkham LS. PCV10 elicits Protein D IgG responses in Papua New Guinean children but has no impact on NTHi carriage in the first two years of life. Vaccine 2021;39:3486-92. [PMID: 34024658 DOI: 10.1016/j.vaccine.2021.05.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 de Sévaux JL, Venekamp RP, Lutje V, Hak E, Schilder AG, Sanders EA, Damoiseaux RA. Pneumococcal conjugate vaccines for preventing acute otitis media in children. Cochrane Database Syst Rev 2020;11:CD001480. [PMID: 33231293 DOI: 10.1002/14651858.CD001480.pub6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Vemer P, Postma MJ. A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children. Hum Vaccin Immunother 2014;10:1841-9. [PMID: 25424791 DOI: 10.4161/hv.29008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
86 Hau I, Levy C, Caeymaex L, Cohen R. Impact of Pneumococcal Conjugate Vaccines on Microbial Epidemiology and Clinical Outcomes of Acute Otitis Media. Pediatr Drugs 2014;16:1-12. [DOI: 10.1007/s40272-013-0044-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
87 Collins S, Vickers A, Ladhani SN, Flynn S, Platt S, Ramsay ME, Litt DJ, Slack MP. Clinical and Molecular Epidemiology of Childhood Invasive Nontypeable Haemophilus influenzae Disease in England and Wales. Pediatr Infect Dis J 2016;35:e76-84. [PMID: 26569188 DOI: 10.1097/INF.0000000000000996] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
88 Ordóñez JE, Orozco JJ. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia. Cost Eff Resour Alloc 2015;13:6. [PMID: 25878563 DOI: 10.1186/s12962-015-0032-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
89 Marchisio P, Nazzari E, Torretta S, Esposito S, Principi N. Medical prevention of recurrent acute otitis media: an updated overview. Expert Rev Anti Infect Ther 2014;12:611-20. [PMID: 24678887 DOI: 10.1586/14787210.2014.899902] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
90 Nicholls TR, Leach AJ, Morris PS. The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: Systematic review and meta-analyses of randomised controlled trials. Vaccine 2016;34:703-13. [PMID: 26742947 DOI: 10.1016/j.vaccine.2015.12.048] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
91 Andrade AL, Ternes YM, Vieira MA, Moreira WG, Lamaro-Cardoso J, Kipnis A, Cardoso MR, Brandileone MC, Moura I, Pimenta FC, da Gloria Carvalho M, Saraiva FO, Toscano CM, Minamisava R. Direct effect of 10-valent conjugate pneumococcal vaccination on pneumococcal carriage in children Brazil. PLoS One 2014;9:e98128. [PMID: 24892409 DOI: 10.1371/journal.pone.0098128] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
92 Kaur R, Pichichero M. Lipidation of Haemophilus influenzae Antigens P6 and OMP26 Improves Immunogenicity and Protection against Nasopharyngeal Colonization and Ear Infection. Infect Immun 2022;:e0067821. [PMID: 35435727 DOI: 10.1128/iai.00678-21] [Reference Citation Analysis]
93 Krone CL, Wyllie AL, van Beek J, Rots NY, Oja AE, Chu ML, Bruin JP, Bogaert D, Sanders EA, Trzciński K. Carriage of Streptococcus pneumoniae in aged adults with influenza-like-illness. PLoS One 2015;10:e0119875. [PMID: 25789854 DOI: 10.1371/journal.pone.0119875] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
94 Mrkvan T, Pelton SI, Ruiz-Guiñazú J, Palmu AA, Borys D. Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience. Expert Rev Vaccines 2018;17:797-818. [PMID: 30185083 DOI: 10.1080/14760584.2018.1516551] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]